Repligen Corporation
176.93USD
-1.7800 (-1.00%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on RGEN.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.46▼ | $0.47 | 1 | 2 |
| Next quarter | $0.56▼ | $0.6 | 1 | 0 |
| Current year | $2.06▲ | $2 | 1 | 3 |
| Next year | $2.7▲ | $2.55 | 1 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.45 | $0.54 | +0.09 (+20.4%) |
| 2026-03-31 | $0.39 | $0.48 | +0.09 (+22.9%) |
| 2025-12-31 | $0.44 | $0.49 | +0.05 (+10.4%) |
| 2025-09-30 | $0.42 | $0.46 | +0.04 (+10.6%) |
122 ratings from 24 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Maintained | Hold | $145 $180 | Oct 19, 2026 |
| Barclays | Maintained | Overweight | $175 $225 | Oct 7, 2026 |
| UBS | Maintained | Buy | $195 $225 | Sep 9, 2026 |
| Wells Fargo | Maintained | Overweight | $180 $185 | Jul 30, 2026 |
| JP Morgan | Maintained | Overweight | $165 $175 | Jul 29, 2026 |
| Benchmark | Upgraded from Hold | Buy | $185 | Jul 7, 2026 |
| Evercore ISI Group | Maintained | Outperform | $150 $160 | Jul 6, 2026 |
| HSBC | Maintained | Buy | $170 $150 | Jun 3, 2026 |
| JP Morgan | Maintained | Overweight | $180 $165 | May 6, 2026 |
| Barclays | Maintained | Overweight | $145 $160 | May 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $165 $145 | Apr 20, 2026 |
| Roth Capital | Initiated | Buy | $160 | Apr 17, 2026 |
| Barclays | Maintained | Overweight | $175 $145 | Apr 14, 2026 |
| Evercore ISI Group | Maintained | Outperform | $170 $140 | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $180 $208 | Mar 23, 2026 |
| UBS | Maintained | Buy | $200 $195 | Feb 25, 2026 |
| Barclays | Maintained | Overweight | $200 $175 | Feb 25, 2026 |
| Wells Fargo | Maintained | Overweight | $190 $180 | Feb 25, 2026 |
| Evercore ISI Group | Maintained | Outperform | $180 $170 | Feb 25, 2026 |
| UBS | Maintained | Buy | $190 $200 | Jan 16, 2026 |
| Barclays | Maintained | Overweight | $175 $200 | Dec 15, 2025 |
| Wells Fargo | Maintained | Overweight | $175 $190 | Dec 15, 2025 |
| Canaccord Genuity | Maintained | Hold | $150 $165 | Oct 29, 2025 |
| Barclays | Maintained | Overweight | $160 $175 | Oct 29, 2025 |
| Evercore ISI Group | Maintained | Outperform | $155 $175 | Oct 7, 2025 |
60 filings from 19 insiders · 14 buy / 6 sell over 6m
Officers and directors of RGEN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Douglass Brian RobbOfficer, CHIEF PRODUCT OFFICER | GrantStock Option (Right to Buy) | 675 | — | — | Oct 6, 2026 |
| Douglass Brian RobbOfficer, CHIEF PRODUCT OFFICER | Grant | 700 | — | — | Oct 6, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | ExerciseStock Option (Right to Buy) | 4.2k | — | — | Oct 5, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Sell | 4.2k | $190.00 | $798k | Oct 5, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Exercise | 4.2k | $154.96 | $651k | Oct 5, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Sell | 1.3k | $178.75 | $238k | Oct 5, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Tax | 1.2k | $181.70 | $227k | Oct 2, 2026 |
| Garland Jason KOfficer, CFO | Tax | 421 | $189.68 | $80k | Sep 25, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | ExerciseStock Option (Right to Buy) | 4.5k | — | — | Sep 24, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | ExerciseStock Option (Right to Buy) | 8.4k | — | — | Sep 24, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Sell | 4.5k | $190.00 | $863k | Sep 24, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Exercise | 4.5k | $155.38 | $706k | Sep 24, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Sell | 8.4k | $190.00 | $1.60M | Sep 24, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Exercise | 8.4k | $154.96 | $1.30M | Sep 24, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | ExerciseStock Option (Right to Buy) | 5.4k | — | — | Sep 21, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Sell | 5.4k | $180.00 | $977k | Sep 21, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Exercise | 5.4k | $141.79 | $769k | Sep 21, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Sell | 3.0k | $165.90 | $504k | Sep 4, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Tax | 2.8k | $169.61 | $482k | Sep 3, 2026 |
| Hughes ViolettaOfficer, CHIEF ACCOUNTING OFFICER | Tax | 277 | $170.02 | $47k | Sep 1, 2026 |
No analyst notes on RGEN yet.
Analyst Ratings
20 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 15 | 4 | 0 | 0 | Buy2.05 |
| 1 mo ago | 3 | 15 | 4 | 0 | 0 | Buy2.05 |
| 2 mo ago | 3 | 15 | 4 | 0 | 0 | Buy2.05 |
| 3 mo ago | 4 | 15 | 3 | 0 | 0 | Buy1.95 |
Members whose judged calls on RGEN have played out most reliably.
No settled calls on RGEN yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice